Literature DB >> 20352147

The role of garlic in hepatopulmonary syndrome: a randomized controlled trial.

Binay K De1, Deep Dutta, Subrata K Pal, Subhabrata Gangopadhyay, Sumanta Das Baksi, Adyapad Pani.   

Abstract

BACKGROUND: Increased nitric oxide production in cirrhosis has been commonly implicated in the genesis of hepatopulmonary syndrome (HPS). Initial studies suggested that garlic, a constituent of the daily diet, may have a role in the treatment of HPS by altering nitric oxide production.
OBJECTIVE: To evaluate the effects of oral garlic supplementation on arterial blood gas parameters, and overall morbidity and mortality in patients with HPS.
METHODS: Twenty-one and 20 HPS patients were randomly assigned to receive either oral garlic supplementation or placebo, respectively, and were evaluated monthly over a period of nine to 18 months.
RESULTS: After nine months, garlic supplementation was associated with a 24.66% increase in baseline arterial oxygen levels (83.05 mmHg versus 66.62 mmHg; P<0.001), compared with only a 7.37% increase (68.75 mmHg versus 64.05 mmHg; P=0.02) among subjects in the placebo group. There was also a 28.35% decrease in alveolar-arterial oxygen gradient (21.35 mmHg versus 29.77 mmHg; P<0.001) among patients with HPS who received garlic, in contrast with only a 10.73% decrease (29.11 mmHg versus 32.61 mmHg; P=0.12) among those in the placebo group. After nine months, the arterial oxygen level was significantly higher (83.05 mmHg versus 68.75 mmHg; P<0.001) and the alveolar-arterial oxygen gradient was significantly lower (21.35 mmHg versus 29.11 mmHg; P<0.001) among patients receiving garlic compared with those receiving placebo. Reversal of HPS was observed in 14 of 21 patients (66.67%) on garlic supplementation (intent-to-treat analysis) and in one of 20 patients (5%) on placebo. Two of 21 patients undergoing garlic supplementation died during follow-up in contrast to seven of 20 patients who were on placebo.
CONCLUSIONS: Garlic supplementation may be beneficial in patients with HPS for the reversal of intrapulmonary shunts as well as reducing hypoxemia and mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352147      PMCID: PMC2852224          DOI: 10.1155/2010/349076

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  29 in total

1.  Garlic and its active metabolite allicin produce endothelium- and nitric oxide-dependent relaxation in rat pulmonary arteries.

Authors:  David D Ku; Tarek T Abdel-Razek; Jun Dai; SangAe Kim-Park; Michael B Fallon; Gary A Abrams
Journal:  Clin Exp Pharmacol Physiol       Date:  2002 Jan-Feb       Impact factor: 2.557

2.  Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome.

Authors:  Mehri Najafi Sani; Hamid-Reza Kianifar; Abdolrazagh Kianee; Gholamreza Khatami
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression.

Authors:  Binay K De; Sambit Sen; Pranab K Biswas; Sanjay K Mandal; Debasish Das; Utpalendu Das; Supriya Guru; Kausik Bandyopadhyay
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Pharmacokinetics of the garlic compound S-allylcysteine.

Authors:  S Nagae; M Ushijima; S Hatono; J Imai; S Kasuga; H Matsuura; Y Itakura; Y Higashi
Journal:  Planta Med       Date:  1994-06       Impact factor: 3.352

5.  Spontaneous improvement in a patient with the hepatopulmonary syndrome assessed by serial exercise tests.

Authors:  K B Saunders; S S Fernando; H R Dalton; A Joseph
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

Review 6.  Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease.

Authors:  M Castro; M J Krowka
Journal:  Clin Chest Med       Date:  1996-03       Impact factor: 2.878

7.  Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial.

Authors:  G A Abrams; M B Fallon
Journal:  J Clin Gastroenterol       Date:  1998-10       Impact factor: 3.062

8.  Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome.

Authors:  Federico P Gómez; Graciela Martínez-Pallí; Joan A Barberà; Josep Roca; Miquel Navasa; Robert Rodríguez-Roisin
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

Review 9.  Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders.

Authors:  Julie L Huffmyer; Edward C Nemergut
Journal:  Respir Care       Date:  2007-08       Impact factor: 2.258

10.  Pulmonary arterial coil embolization for the management of persistent type I hepatopulmonary syndrome after liver transplantation.

Authors:  Nael E A Saad; David E Lee; David L Waldman; Wael E A Saad
Journal:  J Vasc Interv Radiol       Date:  2007-12       Impact factor: 3.464

View more
  18 in total

Review 1.  Resolution of severe hepato-pulmonary syndrome following transjugular portosystemic shunt procedure.

Authors:  Michael C Wallace; Alan L James; Martin Marshall; Nickolas Kontorinis
Journal:  BMJ Case Rep       Date:  2012-06-01

Review 2.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 3.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 4.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

Review 5.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

Review 6.  Hepatopulmonary Syndrome.

Authors:  Yong Lv; Daiming Fan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

Review 7.  Hepatopulmonary syndrome: update on pathogenesis and clinical features.

Authors:  Junlan Zhang; Michael B Fallon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

8.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

Review 9.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

10.  Modulation of Lung Function by Increased Nitric Oxide Production.

Authors:  Md Nazrul Islam; Ram Lochan Yadav; Prakash Kumar Yadav
Journal:  J Clin Diagn Res       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.